Clinical trials: Staphylococcal Sepsis
Staphylococcus Aureus Bacteremia
Clinical Trial Comparing Safety and Pharmacokinetics of Standard Antibiotic Therapy, Plus Aurexis® or Placebo, for Treatment of Staphylococcus Aureus Bacteremia (SAB)
Hospitalized patients at least 18 years of age, with Staphylococcus aureus bacteremia (SAB) will be enrolled into the study and receive one dose of Aurexis® intravenously on Study Day 1, and will be followed until Study Day 57.
- Trial name
- NCT00198302
- Testing
- Aurexis®
- Volunteers
- 60 people
- Sponsor
- Bristol-Myers Squibb
Toxic Shock Syndrome
Efficacy of IntraVenous ImmunoGlobulins in Toxic Shock Syndromes: a Paediatric Pilot Study
Staphylococcus aureus and Streptococcus pyogenes produce many virulence factors. Some of them are responsible for severe infections in humans. Superantigen toxins synthesized by S. aureus or by S.
- Trial name
- IVIG (NCT02219165)
- Testing
- Intravenous human immunoglobulin, Albumin
- Where
- France
- Volunteers
- 30 people
- Sponsor
- Hospices Civils de Lyon
Immune Response To Sepsis, Staphylococcus Aureus Infection
Immune Resolution After Staphylococcus Aureus Bacteremia
The purpose of this study is to determine how monocyte HLA-DR and other markers of immune function change with time in patients with and without prior immune dysfunction who survive sepsis from Staphylococcus aureus bacteremia.
- Trial name
- NCT01879761
- Where
- United States
- Volunteers
- 102 people
- Sponsor
- University of Chicago